< 1 minute read
Sep. 17, 2021

BMS-986251: A Selective RORgt Inverse Agonist

BMS-986251

selective RORgt inverse agonist entered clinical dev. (psoriasis), discontinued from HTS and SBDD ACS Med. Chem. Lett., Apr. 10, 2020 Bristol Myers Squibb, Princeton, NJ

drughunter.com
Drug Hunter Team

BMS-986251 is an inverse agonist of RORgt, a hot target in inflammation for a significant period. Unfortunately it looks like development hit a wall in this space, and several publications of various company’s RORgt modulators have appeared in the last several months. Chemically, 251 is interesting with 5 stereocenters, none of which look [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in